There is increasing evidence that modulation of ATG4B by either si/shRNA-mediated knockdown or the expression of a dominant negative construct results in a benefit in multiple cancer models, including breast, pancreatic and lung cancer (Table 1). This evidence concerns the gene ATG4B and lung carcinoma.